Infusystems ($INFU) released Fourth Quarter 2015 and Full Year 2015 earnings today which were very good. The company has executed very well over the past 3 years and momentum is really building in terms of revenue growth and earnings growth. I wanted to cover some of my thoughts about the 2015 10-K, conference call, and news release. I’ve been invested in $INFU for a few years now, and I believe the business is still on the right track to keep growing and producing cash flow for the foreseeable future. Highlights for the full year 2015: Revenue of $72.1m...
InfuSystem Holdings Q2 2013 Review
$INFU released their 2013 Q2 earnings and completed their conference call. You can read the 10Q and conference call transcripts from the links. Since the recent failed take private situation, I wanted to review what is happening with the company. Positive Revenue up 4% from Q2 2012 Management has made strides in expanding their business model outside of the oncology market. Meaningful revenue was not shown this quarter, but it’s good to see that the company is expanding to other markets. Long-term care is one of markets, which is a good market to enter, along with post-surgical pain. These...
Ryan Morris makes his initial bid for INFU
Last night, Meson Capital Partners (i.e. Ryan Morris) filed the anticipated offer to purchase InfuSystems. The offer was for a price per share of between $1.85 to $2.00 in cash. I view this as an initial offer, as the price is at the low end of the range I was expecting. If you want to read the letter, click here and read the short letter. From the language in the letter, it sounds like a purchase can happen quickly if the special committee and Meson Capital can agree upon a satisfactory price. $INFU closed the day yesterday at $1.55...